Prior to its 25th Symposium, the Federal Association of Contract Research Organisations (BVMA e.V.) in Germany announced the election of the new Executive Board. Martin Krauss was elected to serve as President. Martin Krauss is co-founder and Managing Director of FGK Clinical Research GmbH and has been a member of the Board before. Ralf Freese from CTC North GmbH & Co. KG was appointed Vice President. Also joining the Board is Dr Yvonne Rollinger, Managing Director of OmniComm Europe GmbH.
Dr Dagmar Chase, Managing Director of Clinrex GmbH, a Board member since 1993 and President since 2001, as well as Dr Michael Gierend, Managing Director of medicomp GmbH, Board member since 1997 and Vice President for 16 years, were no longer standing for re-election.
Dr Dagmar Chase about the new appointments: “The BVMA is an important stakeholder of clinical research in Germany. It was very important for us, the previous Board members, to have a smooth transition to the new executive leadership, and this can now be accomplished. A new generation will now take over leadership, but will still be supported by previous Board members who continue their membership in the association. The new Board with Martin Krauss as President is well-positioned and well-prepared to continue the Association’s successful work.”
“The new Board is looking forward to take on its duties and new challenges”, the new President Martin Krauss commented on his appointment. “Clinical research faces constant changes - digitalization is just one example - and new developments come up more and more frequently. A close cooperation and exchange of information between members, representatives from industry, regulatory bodies, ethics committees, and other stakeholders are essential to keep up with these growing demands. The BMVA will also focus in the future on keeping Germany attractive for clinical research and strengthening clinical research for the patient’s benefit. I would like to express gratitude to Dagmar Chase, who has been the BVMA’s president for many years, and has made the BVMA an important stakeholder.”
The BVMA was founded in July 1991 as a representative body for CROs (Contract Research Organisations) based in German-speaking countries. The current 41 members are service providers in research and development of pharmaceuticals and medical devices. Throughout Germany, the BVMA represents about 4000 employees in clinical research. In the past years, the association has successfully strived to be represented in relevant regulatory bodies. As a co-founder and member of the European umbrella organisation (European CRO Federation, EUCROF), the BVMA also ensures its international position. The current President of the EUCROF, Dr Martine Dehlinger-Kremer, is a BVMA member. The BVMA is based in München, Germany.
Every year in November, the BVMA organises a symposium, which became (with more than 300 participants) one of the most important conferences in clinical research. At the same time, the symposium has served for the last 25 years as an established platform for the exchange of information between stakeholders in this field.